Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/28756

Dicyclohexylcarbodiimide: Target Organs and Levels of Evidence for GMM-09

Toxicology Studies of Dicyclohexylcarbodiimide (CASRN 538-75-0) in F344/N Rats, B6C3F1 Mice, and Genetically Modified (FVB Tg.AC HEMIZYGOUS) Mice and Carcinogenicity Study of Dicyclohexylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)

Chemical (Study Title)
CASRN
Peer Review Date Route/Exposure Levels Study Laboratory
Dicyclohexylcarbodiimide
538-75-0
08/28/2006 Topical Application
0, 0.75, 1.5, 3, 6, or 12 mg/kg; 15/group
BioReliance, Inc

Levels of evidence information for Dicyclohexylcarbodiimide in Female Tg.AC Hemizygous Mice
  Female Tg.AC Hemizygous Mice
  20 Week
Neoplastic Lesions
  • Skin (site of application): squamous cell papilloma (0/10, 0/10, 1/10, 3/10, 6/10, 8/10)
Non-Neoplastic Lesions
  • Skin (site of application): chronic active inflammation of the dermis; epidermal hyperplasia

Levels of evidence information for Dicyclohexylcarbodiimide in Female p53 Haploinsufficient Mice
  Female p53 Haploinsufficient Mice
  27 Week
Levels of Evidence No evidence
Neoplastic Lesions None
Non-Neoplastic Lesions
  • Skin (site of application): focal epidermal hyperplasia; focal chronic active inflammation of the dermis; focal ulcer; focal chronic active inflammation of the subcutaneous tissue